New drug cocktail aims to tame advanced colon cancer

NCT ID NCT04564898

Ongoing Disease control Sponsor: Gruppo Oncologico del Nord-Ovest Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study is testing whether a combination of three drugs—trifluridine/tipiracil, capecitabine, and bevacizumab—can safely control metastatic colorectal cancer in people who are not healthy enough for standard intensive chemotherapy. The first part finds the best dose, and the second part checks how well the combo shrinks tumors. About 48 adults with previously untreated metastatic disease are taking part.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: trifluridine/tipiracil, capecitabine, and bevacizumab
What this could lead to: If successful, this could offer a new, less intensive treatment option for people with metastatic colorectal cancer who cannot tolerate strong chemotherapy.
What could go wrong: This is an early-phase trial with only 48 participants, so the combination may prove too toxic or not effective enough. Results may not apply to all patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for COLORECTAL CANCER METASTATIC are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

colorectal cancer

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

COLORECTAL CANCER METASTATIC

Contacts and locations

Locations

Azienda Ospedaliero Universitaria Pisana

Pisa, PI, 56126, Italy
Fondazione IRCCS Istituto Nazionale Tumori

Milan, MI, 20133, Italy

More trials for these conditions

Other studies related to the condition(s) this trial covers.